| |
 |
 |
1.Yen-Yang Chen, Cheng-Hua Huang*, Yeh Tang, Hock-Lien Eng.
Concurrent chemoradiotherapy for unresectable thymic carcinoma,. Chang Gung Medical Journal Vol.27,No.7,p515-22, Jul,2004.(non-SCI)
2.Chiu YC, Lin JW, Changchien CS, Huang CC, Liu SY, Yi LN, Chiu KW, Wu KL, Chen YY, Chou FF, Hu TH*.Clinicaopathological characteristics and prognosis of patients with small intestinal stromal tumors. Journal of the Formosan medical association.2005;104:905-912. (SCI; IF=3.282; Medicine, general & internal 53/168)
3.Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, Liu JS, Huang CH*. Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients. Clinical Neurology and Neurosurgery 2006; 108: 150–156 (SCI; IF=1.876; Surgery 141/211).
4.Tai lin Huang, Yeh Tang, Kun ming Rau, Yeng yang Chen, Cheng-hua Huang*. Extrapulmonary small cell carcinoma-A medical center’s experience. Chang Gung Med J. 2006;29:590-595. (non-SCI)
5.Chen JS*, Rau KM, Chen YY, Huang JS, Yang TS, Lin YC, Liau CT, Lee KD, Su YC, Kao RH. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 2009 Apr;63(5):819-25. (SCI; IF=3.333; Oncology 165/242)
6.Su Yu Li, Chien ting Liu, Tai Jan Chiu, Shau hsuan Li, Tai lin Huang, Chen YY Yeh Tang, Rau KM, Cheng-hua Huang*. Meatstatic mucinous colorectal cancer : An important subtype of colorectal cancer with poor response to chemotherapy and overall survival. 台灣癌症醫學雜誌, 2010;26:221-230. (non-SCI)
7.Rau KM, Li SH, Chen SM, Tang Y, Huang CH, Wu SC, Chen YY*. Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients. Japanese Journal of Clinical Oncology. 2011 Apr;41(4):455-61. (SCI; IF=3.019; Oncology 180/242)
8.Chen YY, Yeh CN*, Tseng JH, Chen JS, Chen TW, Tsai CY, Cheng CT, Jan YY, Chen MF.Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing kit : A decade experience from Taiwan. Translational oncology. 2011 ; 4:328-325. (SCI; IF=4.243; Oncology 117/242)
9.Jen-Shi Chen, Yen-Yang Chen, Jen-Sheng Huang, Kun-Yun Yeh, Ping-Tsung Chen, Wen-Chi Shen, Hung-Chih Hsu, Yung-Chung Lin and Hung-Ming Wang*. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric cancer. 2012;15:49-55. (SCI; IF=7.370; Gastroenterology & hepatology 18/92)
10.Yen-Yang Chen, Chun-Nan Yeh*, Chi-Tung Cheng, Tsung-Wen Chen, Kun-Ming Rau, Yi-Yin Jan,Miin-Fu Chen.Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World journal of gastroenterology.2011;17:2113-2119. (SCI; IF=5.742; Gastroenterology & hepatology 28/92)
11. Chen YH, Lu HI, Huang CH, Rau KM, Chiu YC, Wang YM, Chen YY, Liu CT, Li SH*.The use of trimodality treatment of locally advanced resectable esophageal squamous cell carcinoma: a single institute experience in southern Taiwan. Journal of Cancer Research and Practice. 2011; Oct 27(5): 200-210.(non-SCI)
12.Jen-Shi Chen,Yen-Yang Chen,Jen-Sheng Huang,Kun-Yun Yeh,Ping-Tsung Chen,Wen-Chi Shen,Hung-Chih Hsu,Yung-Chung Lin,Hung-Ming Wang* . A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer 2012;15:49-55. (SCI; IF=7.370; Gastroenterology & hepatology 18/92)
13.Kun-Ming Rau, Chao-Cheng Huang, Tai-Jan Chiu, Yen-Yang Chen, Chien-Chang Lu, Chien-Ting Liu, Sung-Nan Pei, and Yu-Ching Wei*. Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Experimental and Therapeutic Medicine. 2012 Aug; 4(2): 231–236 (SCI; IF=2.447; Medcine, Research & Experimental 104/140)
14.Chi-Tung Cheng, Shih-Chiang Huang, Ting-Wei Chang, Yi-Yin Jan, Cheng-Hwai Tzeng, Ta-Chung Chao, Yeng-Yang Chen, Ching-Yao Yang, Ching-Liang Ho, Jonathan A Fletcher*.Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Annals of Surgical Oncology 2012;19:3491-3499. (SCI; IF=5.344; Onocology 81/242)
15.Yen-Hao Chen, Yu-Ming Wang, Hung-I Lu, Tao-Chen Lee, Cheng-Hua Huang, Ming-Jang Hsieh, Fu-Min Fang, Kun-Ming Rau, Yen-Yang Chen, Shau-Hsuan Li*.Brain Metastasis in Patients with Esophageal Squamous Cell Carcinoma: A Single Institute Experience in Southern Taiwan. 中華民國癌症醫學會雜誌. 201329:182-189. (non-SCI)
16.Yu-Ching Wei, Fong-Fu Chou, Chien-Feng Li, Wei-Ming Li, Yen-Yang Chen, Jui Lan, Shau-Hsuan Li, Fu-Min Fang, Tsung-Hui Hu, Shih-Chen Yu, Hock-Liew Eng, Yih-Huei Uen, Yu-Fang Tian, Jui-Chu Wang, Hsuan-Ying Huang*.HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease-free survival in patients with gastrointestinal stromal tumours (GISTs). Histopathology. 2013;63:445-454. (SCI; IF=5.087; Pathology 18/77)
17.Chun-NanYeh, Wen-HungChung, Shih-ChiSu, Yen-YangChen, Chi-TungCheng, Yen-LingLin, Wan-ChunChang, RosalineChung-Yee Hui, Kun-ChunChiang, Tsung-WenChen, Yi-YinJan, Chien-WeiChen, Ting-JuiChen, Chih-HsunYang, Shuen-Iu Hung*. Fas/Fas Ligand Mediates Keratinocyte Death in Sunitinib-Induced Hand-Foot Skin Reaction. Journal of investigative dermatology. 2014; 134: 2768 -2775. (SCI; IF=8.551; Dermatology 4/68)
18.Yu-Li Su, Shan-Hsuan Li, Yen-Yang Chen, Hui-Chun Chen, Yen Tang, Cheng-Hua Huang, Fong-Fu Chou, Shih-Chung Wu, and Kun-Ming Rau*. Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1–2 tumor and 1–3 axillary lymph node(s) metastasis. Radiology and Oncology. 2014;48:314-322. (SCI; IF=2.991; Radiology, Nuclear medicine & Medical imaging 65/134)
19.Chih-Chieh Hsu, Chiao-En Wu, Jen-Shi Chen, Jeng-Hwei Tseng, Kun-Chun Chiang, Yu-Yin Liu, Chun-Yi Tsai, Chi-Tung Cheng, Tsung-Wen Chen, Yi-Yin Jan, Ta-Sen Yeh, Yen-Yang Chen and Chun-Nan Yeh*. Imatinib Escalation or Sunitinib Treatment After First-line Imatinib in Metastatic Gastrointestinal Stromal Tumor Patients. Anticancer research. 2014;34:5029-5036. (SCI; IF=2.480; Oncology 209/242)
20.Chien-Feng Li, Li-Tzong Chen, Jui Lan, Fong-Fu Chou, Ching-Yih Lin, Yen-Yang Chen, Tzu-Ju Chen, Shau-Hsuan Li, Shih-Chen Yu, Fu-Ming Fang, Hui-Chun Tai, and Hsuan-Ying Huang*. AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis. Oncotarget. (non-SCI) 2014;5:11588-11603.
21.Meng-Che Hsieh, Po-Hui Chiang, Kun-Ming Rau, Yen-Yang Chen, Yo-Li Su, Cheng-Hua Huang*.Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) has a Better Survival than GC (Gemcitabine and Cisplatin). 中華民國癌症醫學會雜誌. 2014;1:197-207. (non-SCI)
22.Chun-Nan Yeh, Chueh-Chuan Yen, Yen-Yang Chen, Chi-Tung Cheng, Shih-Chiang Huang, Ting-Wei Chang, Fang-Yi Yao, Yung-Chan Lin, Yao-Shan Wen, Kun-Chun Chiang, Jen-Shi Chen, Ta-Sen Yeh, Cheng-Hwai Tzeng, Ta-Chung Chao, and Jonathan A. Fletcher. Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget. 2014;5:4071-4086. (non-SCI)
23.Ming-Chun Ma, Yen-Yang Chen, Shau-Hsuan Li, Yu-Fan Cheng, Chih-Chi Wang, Tai-Jan Chiu, Sung-Nan Pei, Chien-Ting Liu, Tai-Lin Huang, Chen-Hua Huang, Yu-Li Su, Yen-Hao Chen, Sheng-Nan Lu, Kun-Ming Rau*. Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. Scientific world journal. 2014:16013.(non-SCI)
24.Yen-Yang Chen , Chun-Nan Yeh, Chi-Tung Cheng , Chao-En Wu , Kun-Chun Chiang , Tsung-Wen Chen , Chih-Chi Wang , Jen-Shi Chen , Ta-Sen Yeh
Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study. Translational Oncology. 2014;7:620-625. (SCI; IF=4.243; Oncology 117/242)
25.Chien-Ting Liu, Yi-Chun Chiu, and Yen-Yang Chen*. Multiple Endocrine Neoplasia Type 1 With GastricNeuroendocrine Tumor Presented With Gastric Polyposis. Clinical Gastroenterology and Hepatology. 2015;13:e45 11.382; (SCI; IF=11.382; GASTROENTEROLOGY & HEPATOLOGY 8/92)
26.Shih-Chun Chang, Chien-Hung Liao, Shang-Yu Wang, Chun-Yi Tsai, Kun-Chun Chiang, Chi-Tung Cheng, Ta-Sen Yeh, Yen-Yang Chen, Ming-Chun Ma, Chien-Ting Liu, Chun-Nan Yeh*.Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.Medicine 2015;94:1-6. (SCI; IF= 1.889; MEDICINE, GENERAL & INTERNAL 99/168)
27.Chi-Tung Cheng, Yin-Yi Chu, Chun-Nan Yeh*, Shih-Chiang Huang, Ming Huang Chen, Shang-Yu Wang, Chun-Yi Tsai, Kun-Chun Chiang, Yen-Yang Chen, Ming-Chun Ma,Chien-Ting Liu, Tsung-Wen Chen, Ta-Sen Yeh. Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. Oncotargets and therapy. 2015;8:1899-1907 4.147. (SCI; IF= 4.147;BIOTECHNOLOGY & APPLIED MICROBIOLOGY 53/159)
28.Meng-CheHsieh, Po-Hui Chiang, Kun-Ming Rau, Yen-YangChen, Yu-Li Su, Cheng-Hua Huang*. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.Urologic oncology-seminars and original investigations. 2015 Nov; 33(11) : 495.e9-495.e14 (SCI; IF= 3.498; UROLOGY & NEPHROLOGY 32/90)
29.Jen-Hao Yeh, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen , Kwong-Ming Kee, Chung-Mou Kuo, Yi-Hao Yen, Yu-Fan Cheng, Yen-Yang Chen, Hsuan-Chi Hsu, Sheng-Nan Lu*. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLOS ONE 2015;10:14489 (SCI; IF= 3.240; MULTIDISCIPLINARY SCIENCES 26/73
30.Meng-Che Hsieh, Yu-Li Su,Po-Hui Chiang,Kun-Ming Rau,Yen-Yang Chen,Cheng-Hua Huang*. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy. International Journal of Urology. 2016;23:385-389 (SCI; IF= 3.369; UROLOGY & NEPHROLOGY 36/90)
31.Meng-Che Hsieh,Cheng-Hua Huang,Po-Hui Chiang,Yen-Yang Chen,Yeh Tang,Yu-Li Su*.Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. Journal of Cancer. 2016;7:1347-1352 (SCI;IF=4.207; ONCOLOGY 119/242)
32.Chun-Nan Yeh, Shang-Yu Wang, Yen-Yang Chen, Ming-Huang Chen, Kun-Chun Chiang, Chi-Tung Cheng, Chun-Yi Tsai, Chih-Chi Wang, Ta-Sen Yeh*, Tse-Ching Chen.A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma. Anticancer research. 2016;36:4249-4258 (SCI;IF=2.480; ONCOLOGY 209/242)
33.Chien-Ting Liu, Jen-shi Chen, Li-Tzong Chen, Yan-Shen Shan, Chang-Hsien Lu, Yu-Li Su, Fan-Chen Ku, Wen-Chi Chou*, Yen-Yang Chen.The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia-Pacific Journal of Clinical Oncology.2016;12:396-402 (SCI;IF=2.601; ONCOLOGY 199/242)
34.Chien-Feng Li, I-Chieh Chuang, Ting-Ting Liu,Ko-Chin Chen, Yen-Yang Chen, Fu-Min Fang, Shau-Hsuan Li, Tzu-Ju Chen, Shih-Chen Yu, Jui Lan, Hsuan-Ying Huang*.Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors. Oncotarget.2016;7:49986-49997. (non-SCI)
35.Chun-Nan Yeh*, Shang-Yu Wang, Chun-Yi Tsai, Yen-Yang Chen, Ching-Ting Liu, Kun-Chun Chiang, Tsung-Wen Chen, Yu-Yin Liu, Ta-Sen Yeh.Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.International journal of surgery. 2017;39:30-36 (SCI;IF=6.071; SURGERY 15/211)
36.Chien-Feng Li, Ting-Ting Liu, I-Chieh Chuang, Yen-Yang Chen, Fu-Min Fang, Ti-Chun Chan, Wan-Shan Li, and Hsuan-Ying Huang*.PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget 2017;8:19997-20010. (non-SCI)
37.Chien-Feng Li, Fu-Min Fang, Yen-Yang Chen, Ting-Ting Liu, Ti-Chun Chan, Shih-Chen Yu, Li-Tzong Chen, Hsuan-Ying Huang*.Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.Clinical Cancer Research. 2017;23:4908-4918 (SCI;IF=12.531; ONCOLOGY 18/242)
38.Chun-Nan Yeh, Ming-Huang Chen, Yen-Yang Chen, Ching-Yao Yang, Chueh-Chuan Yen, Chin-Yuan Tzen, Li-Tzong Chen, Jen-Shi Chen*.A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget.2017;8:44121-44130. (non-SCI)
39.Ming-Chun Ma, Yi-Ju Chen, Tai-Jan Chiu, Jui Lan, Chien-Ting Liu, Yi-Ching ChenHsin-Ho Tien & Yen-Yang. Chen*.Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. BMC CANCER.2018;18:227.(SCI;IF= 4.430; ONCOLOGY 109/242)
40.Ming-Chun Ma, Tai-Jan Chiu, Hung-I Lu, Wan-Ting Huang, Chien-Ming Lo, Wan-Yu Tien, Ya-Chun Lan, Yen-Yang Chen, Chang-Han Chen, Shau-Hsuan Li*. SIRT1 overexpression is an independent prognosticator for patients with esophageal squamous cell carcinoma.Journal of Cardiothoracic Surgery. 2018;13:25 (SCI;IF=1.637; CARDIAC & CARDIOVASCULAR SYSTEM 123/141)
41.Jen-Shi Chen*, Chun-Nan Yeh, Chi-Tung Cheng, Chueh-Chuan Yen, Yen-Yang Chen, Shih-Chiang Huang, Kun-Chun Chiang, Ta-Sen Yeh, San-Chi Chen, Ta-Chung Chao, Muh-Hwa Yang, Yee Chao. Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. Oncology Letters. 2018;16:3070-3082. (non-SCI)
42.Chien-Feng Li, Ting-Ting Liu, Jui-Chu Wang, Shih-Chen Yu, Yen-Yang Chen, Fu-Min Fang, Wan-Shan Li, Hsuan-Ying Huang*.Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors. Journal of Clinical Medicine. 2018;7:408 (SCI;IF=4.241; MEDICINE, GENERAL & INTERNAL 39/168)
43.Yu-Shin Hung, Jen-Shi Chen, Yen-Yang Chen, Chang-Hsien Lu, Pei-Hung Chang, Wen-Chi Chou*. Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Cancers. 2018;10:432 (SCI;IF=6.639; ONCOLOGY 51/242)
44.Jen-Shi Chen, Chia-Yen Hung, Hung Chang, Chien-Ting Liu,Yen-Yang Chen, Chang-Hsien Lu, Pei-Hung Chang, Yu-Shin Hung, Wen-Chi Chou*.Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. Cancers. 2018;10:501 (SCI;IF=6.639; ONCOLOGY 51/242)
45.Yen YangChen,Chi Tung Cheng, Ren Chin Wu, Chun Yi Tsai, Kun Chun Chiang, Ta Sen Yeh, Ming Huang Chen*, Chun Nan Yeh. MET RON dual inhibitor, BMS 777607, suppresses cholangiocarcinoma cell growth, and MET RON upregulation indicates worse prognosis for intra hepatic cholangiocarcinoma patients. Oncology Reports. 2018;40:1411-1421 (SCI,IF=3.906; ONCOLOGY 133/242)
46.Wen-Chi Chou*, Yen-Yang Chen, Chia-Yen Hung, Jen-Shi Chen, Chang-Hsien Lu, Pei-Hung Chang..Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study inTaiwan, 2010–2016. Cancer Management and Research 2019;11:2119-2127 (SCI, IF=3.989; ONCOLOGY 128/242)
47.Shu-Hui Lee,Pei-Hung Chang,Ping-Tsung Chen,Chang-Hsien Lu,Yu-Shin Hung,Ngan-Ming Tsang,Chia-Yen Hung,Jen-Shi Chen,Hung-Chih Hsu,Yen-Yang Chen,Wen-Chi Chou*Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Medicine. 2019;8:3471-3478 (SCI;IF=4.452; ONCOLOGY 107/242)
48.Chia-Che Wu, Kun-Ming Rau, Wei-Chieh Lee, Meng-Che Hsieh, Jia-Sin Liu, Yen-Yang Chen, and Harvey Yu-Li Su*. Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. Journal of Clinical Medicine. 2019;8:1024 4.241. (SCI;IF=4.241;MEDICINE, GENERAL & INTERNAL 39/168)
49.Ching-Fu Chang,Pei-Wei Huang,Jen-Shi Chen,Yen-Yang Chen,Chang-Hsien Lu,Pei-Hung Chang,Yu-Shin Hung,Wen-Chi Chou*.Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers. 2019;11:57 (SCI;IF=6.639; ONCOLOGY 51/242)
50.Pei-Wei Huang, Ching-Fu Chang, Chia-Yen Hung, Shun-Wen Hsueh, Pei-Hung Chang, Kun-Yun Yeh, Jen-Shi Chen, Yen-Yang Chen, Chang-Hsien Lu, Yu-Shin Hung, Wen-Chi Chou*.Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Medicine. 2019;8:5554-5563. 4.452; (SCI;IF=4.452,ONCOLOGY 107/242)
51.Keng-Hao Liu, Chia-Yen Hung, Shu-Wen Hsueh, Pei-Hung Chang, Yen-Yang Chen, Chang-Hsien Lu, Ping-Tsung Chen, Kun-Yun Yeh, Pei-Wei Huang, Ngan-Ming Tsang, Yu-Shin Hung, Wen-Chi Chou*. Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. Journal of Clinical Medicine. 2019;8:e1402 4.241. (SCI;IF=4.241,MEDICINE, GENERAL & INTERNAL 39/168)
52.Hsiang‐Lan Lai, Yen‐Yang Chen, Chang‐Hsien Lu, Chia‐Yen Hung, Yung‐Chia Kuo, Jen‐Shi Chen, Hung‐Chih Hsu, Ping‐Tsung Chen, Pei‐Hung Chang, Yu‐Shin Hung, and Wen‐Chi Chou*Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan. Cancer Medicine. 2019;8:2085-2094. (SCI;IF=4.452; ONCOLOGY 107/242)
53.Yi-Hao Yen, Yu-Fan Cheng, Jing-Houng Wang, Chih-Che Lin, Yen-Yang Chen, Chee-Chien Yong, Yueh-Wei Liu, Jen-Yu Cheng, Chien-Hung Chen, Tsung-Hui Hu*. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLOS ONE. 2020;15:23000 (SCI;IF=3.240; MULTIDISCIPLINARY SCIENCES 26/73)
54.Shih‑Yu Huang, Cheng‑Hua Huang, Harvey Yu‑Li Su, Yen‑Hao Chen, Tai‑Jan Chiu, Yen‑Yang Chen*.Efficacy and Safety of Uracil‑Tegafur in Patients with Recurrentor Metastatic Thymic Carcinoma.台灣癌症醫學會雜誌.20207:111-115 (non SCI)
55.Shao-Ming Yu, Chang-Hsien Lu, Keng-Hao Liu, Ping-Tsung Chen, Pei-Hung Chang, Chia-Yen Hung, Shun-Wen Hsueh, Kun-Yun Yeh, Yen-Yang Chen, Yu-Shin Hung, Wen-Chi Chou*. External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. Pancreatology. 2020;20:116-124 (SCI;IF=3.996; GASTROENTEROLOGY & HEPATOLOGY 46/92)
56.Chih-Chung Hsu, Keng-Hao Liu, Pei-Hung Chang, Ping-Tsung Chen, Chia-Yen Hung, Shun-Wen Hsueh, Kun-Yun Yeh, Yen-Yang Chen, Chang-Hsien Lu, Yu-Shin Hung, Wen-ChiChou*. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. Journal of Gastroenterology and Hepatology. 2020;35:1694-1703 (SCI;IF=4.029; GASTROENTEROLOGY & HEPATOLOGY 45/92)
57.Tai-Jan Chiu, Yi-Ju Chen, Fang-Ying Kuo, Yen-Yang Chen*. Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.PLOS ONE. 2020;15:24079 (SCI;IF=3.240; MULTIDISCIPLINARY SCIENCES 26/73)
58.Yen-Yang Chen, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, Yen-Hao Chen*. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. PEERJ 2020;8:e10382 (SCI;IF=2.984; MULTIDISCIPLINARY SCIENCES 27/73)
59.Yu-Yin Liu, Yueh-Wei Liu, Yen-Yang Chen, Shih-Ho Wang, Seng-Kee Chuah, Gong-Kai Huang, Yen-Hao Chen*.The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients. Journal of Gastrointestinal Oncology. 2021;12:297-306. (SCI;IF= 2.892; GASTROENTEROLOGY & HEPATOLOGY 70/92)
60.Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang*. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure.Frontiers in Oncology. 2021;11:68334 (SCI;IF=6.244; ONCOLOGY 62/242)
61.Tian-Huei Chu, Yu-Wei Chou, Sheng-Lun Lin, Su-Fan Liu, Hong-Hwa Chen, Wan-Hsiang Hu, Yen-Yang Chen, Guo-Ping Chang-Chien, Jyun-Huan Chang, Meng-Chi Tsai, Chou-Cheng Huang*.A pilot study examining the relationship between environmental contaminants and colorectal cancer at a single medical institute in Taiwan. 台灣衛誌;40:382-393 (non SCI)
62.Yen-Yang Chen,Chao-Long Chen,Chih-Che Lin,Chih-Chi Wang,Yueh-Wei Liu,Wei-Feng Li,Yen-Hao Chen*.Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers 2021;13:4584 (SCI;IF=6.639; ONCOLOGY 51/242)
|
|
